A randomised, double-blind, placebo-controlled, single ascending and multiple ascending dose study of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of lomitapide in Japanese and Caucasian volunteers with elevated LDL-C

Trial Profile

A randomised, double-blind, placebo-controlled, single ascending and multiple ascending dose study of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of lomitapide in Japanese and Caucasian volunteers with elevated LDL-C

Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2014

At a glance

  • Drugs Lomitapide (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Aegerion Pharmaceuticals
  • Most Recent Events

    • 21 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Sep 2013 Planned End Date changed from 1 Apr 2013 to 1 Dec 2013. The trial is expected to be completed in the fourth quarter of 2013 according to an Aegerion Pharmaceuticals media release.
    • 08 Jan 2013 Enrolment of Japanese volunteers was initiated in the fourth quarter of 2012, according to an Aegerion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top